NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia - NICE TAG TA344

Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia - NICE TAG TA344

1.1 Ofatumumab in combination with chlorambucil is recommended as an option for untreated chronic lymphocytic leukaemia only if:

  • the person is ineligible for fludarabine‑based therapy and

  • bendamustine is not suitable and

  • the company provides ofatumumab with the discount agreed in the patient access scheme.

1.2 People whose treatment with ofatumumab is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue ofatumumab until they and their NHS clinician consider it appropriate to stop.

http://www.nice.org.uk/guidance/ta344

 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.